依度沙班、利伐沙班与阿哌沙班在静脉血栓栓塞症患者中的有效性和安全性比较:一项队列研究
这项回顾性队列研究利用日本医院行政数据库,比较依度沙班、利伐沙班和阿哌沙班在静脉血栓栓塞症患者中的有效性和安全性。主要有效性结局为复发性静脉血栓栓塞症,主要安全性结局为颅内出血和胃肠道出血的复合终点,随访长达180天。经倾向性评分匹配加权后,三种药物在预防复发性静脉血栓栓塞症及出血风险方面无显著差异。
要点
- 三种药物预防复发性静脉血栓栓塞症无显著差异。
- 三种药物颅内出血或胃肠道出血风险无显著差异。
核心结论
- 在常规诊疗中,依度沙班、利伐沙班和阿哌沙班在静脉血栓栓塞症治疗中似乎具有相似的有效性和安全性。
研究设计与样本
- 回顾性队列研究,使用日本医院行政数据库,识别开始使用依度沙班、利伐沙班或阿哌沙班的三组静脉血栓栓塞症患者。
- 随访长达180天,采用倾向性评分匹配加权平衡组间基线特征。
主要发现
- 复发性静脉血栓栓塞症:依度沙班 vs 利伐沙班 aIRR 0.77(95%CI 0.45-1.30);依度沙班 vs 阿哌沙班 aIRR 0.92(95%CI 0.54-1.56);利伐沙班 vs 阿哌沙班 aIRR 1.20(95%CI 0.69-2.10),均无显著差异。
- 颅内出血或胃肠道出血复合终点:依度沙班 vs 利伐沙班 aIRR 1.57(95%CI 0.85-2.90);依度沙班 vs 阿哌沙班 aIRR 1.30(95%CI 0.76-2.23);利伐沙班 vs 阿哌沙班 aIRR 0.83(95%CI 0.42-1.64),均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although several studies have compared the effectiveness and safety of rivaroxaban and apixaban in patients with venous thromboembolism (VTE), direct comparison of these drugs with edoxaban is lacking. OBJECTIVE: We compared the effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with VTE. PATIENTS/METHODS: In this retrospective cohort study using a Japanese hospital administrative database, we identified three mutually exclusive groups of patients with VTE beginning treatment with edoxaban, rivaroxaban, or apixaban. Primary effectiveness outcome was recurrent VTE, and principal safety outcome was a composite of intracranial hemorrhage and gastrointestinal bleeding. Subjects were followed for up to 180 days. Baseline characteristics among groups were balanced using propensity score matching weights. RESULTS: Three thousand three hundred sixty-nine edoxaban, 1592 rivaroxaban, and 1998 apixaban initiators were identified. There were no significant differences among the three drugs in the prevention of recurrent VTE (adjusted incidence rate ratio [aIRR], 0.77; 95% confidence interval [CI], 0.45-1.30 for edoxaban vs. rivaroxaban; aIRR, 0.92; 95% CI, 0.54-1.56 for edoxaban vs. apixaban; and aIRR, 1.20; 95% CI, 0.69-2.10 for rivaroxaban vs. apixaban), or in the risk of intracranial hemorrhage or gastrointestinal bleeding (aIRR, 1.57, 95% CI, 0.85-2.90 for edoxaban vs. rivaroxaban; aIRR, 1.30, 95% CI, 0.76-2.23 for edoxaban vs. apixaban; and aIRR, 0.83, 95% CI, 0.42-1.64 for rivaroxaban vs. apixaban). CONCLUSIONS: In routine care, edoxaban, rivaroxaban, and apixaban appear to have similar effectiveness and safety in the treatment of VTE.
引用
- Fukasawa T, Seki T, Nakashima M, et al. Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: A cohort study. J Thromb Haemost. 2022. PMID: 35748327. doi:10.1111/jth.15799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。